Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methylprednisolone hemisuccinate
Drug ID BADD_D01435
Description A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
Indications and Usage Not Available
Marketing Status approved
ATC Code Not Available
DrugBank ID DB14644
KEGG ID D05000
MeSH ID D008776
PubChem ID 16923
TTD Drug ID Not Available
NDC Product Code 22552-0024; 57582-012; 82298-109; 24002-0015; 52128-152
UNII 5GMR90S4KN
Synonyms Methylprednisolone Hemisuccinate | Hemisuccinate, Methylprednisolone | Methylprednisolone Succinate | Succinate, Methylprednisolone | Urbason-Soluble | UrbasonSoluble | Solu-Medrol | Solumedrol | A-MethaPred | Methylprednisolone Sodium Succinate | Sodium Succinate, Methylprednisolone | Methylprednisolone Hemisuccinate Monosodium Salt | 6 alpha-Methylprednisolone Sodium Hemisuccinate | Methylprednisolone Sodium Hemisuccinate | Sodium Hemisuccinate, Methylprednisolone
Chemical Information
Molecular Formula C26H34O8
CAS Registry Number 2921-57-5
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug dependence19.07.06.011--Not Available
Dyspepsia07.01.02.001--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Erythema23.03.06.001--Not Available
Euphoric mood19.04.02.006--
Exophthalmos06.09.04.001; 05.02.02.002--Not Available
Feeling abnormal08.01.09.014--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Gastric haemorrhage07.12.01.001; 24.07.02.007--
Gastrointestinal pain07.01.05.005--
Glaucoma06.03.01.002--
Glucose tolerance impaired14.06.02.001; 05.06.02.001--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hiccups07.01.06.009; 22.12.01.001--
Hirsutism23.02.04.001; 05.05.01.005--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypernatraemia14.05.04.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Infection11.01.08.002--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages